LA JOLLA, Calif., Nov. 08, 2019 (GLOBE NEWSWIRE) — INmune Bio, Inc.?(NASDAQ:?INMB) (the ?Company?),?an immunology company developing treatments that harness the patient?s innate immune system to fight disease, today reported its financial results for the third quarter ended September 30, 2019 and is providing a business update.
News
INmune Bio, Inc. Presents Preliminary Phase I Data at 21st International Conference on Alzheimer’s Drug Discovery
LA JOLLA, Calif., Oct. 05, 2020 (GLOBE NEWSWIRE) — INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announce… […]
News
INmune Bio Co-Founder and CEO RJ Tesi Presents at Cambridge Healthcare Institute?s 7th Annual Immuno-Oncology Summit
LA JOLLA, Calif., Aug. 01, 2019 (GLOBE NEWSWIRE) — INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient?s innate immune system to fight disease, today announced that RJ Tesi, M.D., co-found… […]
News
INmune Bio Inc. to Present at Advances in Immuno-Oncology USA Congress and at World Immunotherapy Congress in October
LA JOLLA, Calif., Oct. 08, 2019 (GLOBE NEWSWIRE) — INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient?s innate immune system to fight disease, announced today that RJ Tesi, M.D., Co-Found… […]
